ACE and heart failure: Activation of the reninangiotensin-aldosterone system (RAAS) has been recognized to participate in the process of ventricle remodeling and heart failure following MI, leaving angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) which suppress RAAS activity as therapeutic options for heart failure [10].